All Pharmaceutical Microbiology articles – Page 4
-
NewsAfro-Caribbean Commercial Science Network (ACCSN) named as winner of Dorothy Jones Diversity and Inclusion Achievement Award 2024
The Afro-Caribbean Commercial Science Network (ACCSN), founded by Daniel Similaki, has been named as this year’s winner of the Dorothy Jones Diversity and Inclusion Achievement Award 2024.
-
NewsAdd some spice: Curcumin helps treat Mycobacterium abscessus
Researchers have found that adding curcumin boosts the efficacy of bedaquiline, an antimycobacterial used to treat tuberculosis, in combating M. abscessus infections. Curcumin is the compound that gives turmeric its characteristic bright orange color.
-
NewsPromising new research shows potential to cure recurrent urinary tract infectionsed
Researchers examine the effectiveness of nanogel as a drug delivery system to direct antibiotics into targeted infected cells to improve UTI treatment.
-
NewsPrevalence of neutralizing antibodies to AAV2 and AAV9 in individuals with Niemann-Pick disease
A new study shows that more than half of individuals with Niemann-Pick disease, type C1 (NPC1) who were tested lacked neutralizing antibodies against either adeno-associated virus (AAV) 2 or AAV9.
-
NewsEradivir announces Phase 2 human challenge study of EV25 in healthy adults infected with influenza
Eradivir, a clinical-stage small molecule immunotherapy biotech company, announced it has begun a Phase 2 challenge study with its antiviral therapeutic, EV25.
-
NewsResearch identifies key antibodies for development of broadly protective norovirus vaccine
A new study identifies powerful antibodies capable of neutralizing a wide range of norovirus strains. The finding could lead to the design of broadly effective norovirus vaccine, as well as the development of new therapeutic antibodies.
-
NewsInsilico Medicine deploys the first bipedal humanoid AI scientist in fully-robotic drug discovery laboratory
Insilico Medicine, a clinical-stage biotechnology company pioneering generative AI for drug discovery and development, has announced the deployment of the first bipedal humanoid in its AI-powered fully-robotic drug discovery laboratory.
-
NewsBAADesign enables the immune escaped etesevimab fully-armed against SARS-CoV-2 Omicron subvariants
BAADesign offers a powerful tool for reengineering monoclonal antibodies to combat emerging SARS-CoV-2 variants, providing a scalable solution for future pandemic preparedness, according to a new study.
-
NewsScientist who deployed glowing stars to detect disease named fellow of the Royal Society of Chemistry
The man who turned the science of glow-in-the-dark stars into ways to detect disease, Professor Richard Willson, has been elected as a fellow of the Royal Society of Chemistry.
-
NewsWe feed gut microbes sugar, they make a compound we need
Gut microbes that were thought to feed exclusively on dietary fiber are also fed sugar from our guts, from which they produce short-chain fatty acids that are crucial to many body functions.
-
NewsNewly launched Enodia Therapeutics is a biotech company with a new approach for targeted protein degradation
Argobio and the Institut Pasteur have announced the launch of Enodia Therapeutics, a groundbreaking French biotech company dedicated to block and degrade disease-causing proteins for treating cancer, inflammatory diseases and viral infections.
-
NewsSuperbugs in our food: a new hope for tackling drug resistance
Researchers highlight the potential of quorum sensing inhibitors (QSIs) as a novel approach to tackle Pseudomonas aeruginosa. The study explores the mechanisms of action of various QSIs and potential applications in food safety and healthcare.
-
NewsStudy reveals how bacteria in microbiome medicine trigger tumor-killing cells
Microbiotica has presented new data on the mechanism of action of MB097, a clinical-stage drug candidate being developed as a co-therapy in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma.
-
NewsScientists invent new drug candidates to treat antibiotic-resistant bacteria
Researchers designed a new family of antibiotics that’s a variation of an existing drug called vancomycin, which is used as a last resort for extremely ill patients. The new version of vancomycin targets, bonds to and renders inactive two different parts of a molecule on the surfaces of pathogenic bacteria.
-
NewsPromising new class of antimalarial drugs discovered
A new study identifies an inhibitor of gene regulation that specifically kills the malaria pathogen. The chromatin remodeler PfSnf2L is a key regulator of genes that play an important role in various stages of the pathogen’s development.
-
NewsScottish bio-tech company secures £3.4m investment
Scottish biotech engineering company uFraction8 has secured £3.4m in new investment following the completion of a funding round led by Foresight Group.
-
NewsScientists uncover how bacterial resistance to synergistic drug treatments is arising
Scientists investigating the potential of combined and more powerful drug treatments have found that antimicrobial resistance to these is arising via the vitamin B2 synthesis pathway.
-
NewsNew therapy may effectively control HIV in Uganda
Clinical trials showed an effective antiviral drug, known as lenacapavir, against HIV in Uganda, and has also been tested for drug resistance in different subtype strains.
-
NewsGround-breaking technique deploys bacterium to deliver drugs directly to the brain
A landmark study using the nasal bacteria technique promises new treatments for neurological disorders by bypassing the blood-brain barrier.
-
NewsNew modeling approach could help design antivirals for shape-shifting viruses
New research utilizes an innovative computational modeling approach to capture the complex and diverse shapes that viral proteins can adopt.